ANI Pharmaceuticals Inc Cash Flow Conversion Efficiency
ANI Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.37 Million) by net assets ($540.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANI Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of ANI Pharmaceuticals Inc (1998–2025)
Cash flow conversion efficiency of ANI Pharmaceuticals Inc from 1998 to 2025. This chart illustrates how ANI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ANI Pharmaceuticals Inc (ANIP) stock price for real-time trading data and today's change.
ANI Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
ANI Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ANI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review ANIP free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dime Community Bancshares, Inc.
NASDAQ:DCOM
|
0.032x |
|
Hagerty Inc
NYSE:HGTY
|
0.237x |
|
Guangdong Goworld Co Ltd
SHE:000823
|
0.022x |
|
Greatech Technology Bhd
KLSE:0208
|
0.034x |
|
Ningbo Haitian Precision Machinery Co Ltd
SHG:601882
|
0.045x |
|
Maxvision Technology Corp
SHE:002990
|
0.031x |
|
FRIEDR.VORW.GRP. ADR/025
F:VH20
|
0.147x |
|
Fermi Inc.
NASDAQ:FRMI
|
-0.047x |
Annual Cash Flow Conversion Efficiency for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of ANI Pharmaceuticals Inc from 1998 to 2025. Also see ANIP total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $540.72 Million | $185.22 Million | 0.343x | +129.30% |
| 2024-12-31 | $428.53 Million | $64.02 Million | 0.149x | -42.54% |
| 2023-12-31 | $457.60 Million | $118.96 Million | 0.260x | +382.05% |
| 2022-12-31 | $338.54 Million | $-31.20 Million | -0.092x | -1095.33% |
| 2021-12-31 | $358.74 Million | $3.32 Million | 0.009x | -88.13% |
| 2020-12-31 | $195.70 Million | $15.27 Million | 0.078x | -63.62% |
| 2019-12-31 | $212.79 Million | $45.63 Million | 0.214x | -36.93% |
| 2018-12-31 | $197.26 Million | $67.07 Million | 0.340x | +50.74% |
| 2017-12-31 | $174.76 Million | $39.42 Million | 0.226x | +39.29% |
| 2016-12-31 | $169.65 Million | $27.47 Million | 0.162x | +50.16% |
| 2015-12-31 | $160.08 Million | $17.26 Million | 0.108x | -31.58% |
| 2014-12-31 | $139.78 Million | $22.03 Million | 0.158x | +217.73% |
| 2013-12-31 | $40.96 Million | $-5.48 Million | -0.134x | +85.08% |
| 2012-12-31 | $28.18 Million | $-25.28 Million | -0.897x | +29.11% |
| 2011-12-31 | $37.82 Million | $-47.87 Million | -1.266x | +39.55% |
| 2010-12-31 | $19.15 Million | $-40.10 Million | -2.094x | -79.87% |
| 2009-12-31 | $15.83 Million | $-18.43 Million | -1.164x | -3.62% |
| 2008-12-31 | $13.83 Million | $-15.54 Million | -1.124x | -4613.67% |
| 2007-12-31 | $29.73 Million | $739.99K | 0.025x | +109.00% |
| 2006-12-31 | $18.07 Million | $-5.00 Million | -0.277x | +77.28% |
| 2005-12-31 | $6.82 Million | $-8.30 Million | -1.217x | -85.52% |
| 2004-12-31 | $15.92 Million | $-10.44 Million | -0.656x | -3.15% |
| 2003-12-31 | $8.68 Million | $-5.52 Million | -0.636x | +25.81% |
| 2002-12-31 | $4.62 Million | $-3.96 Million | -0.857x | -90.38% |
| 2001-12-31 | $4.05 Million | $-1.82 Million | -0.450x | +70.17% |
| 2000-12-31 | $2.13 Million | $-3.21 Million | -1.509x | -360.05% |
| 1999-12-31 | $5.45 Million | $-1.79 Million | -0.328x | +71.62% |
| 1998-12-31 | $2.63 Million | $-3.04 Million | -1.156x | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more